Cargando…
Apatinib in patients with recurrent or metastatic thymic epithelial tumor: a single-arm, multicenter, open-label, phase II trial
BACKGROUND: Thymic epithelial tumors (TETs) are rare malignancies and the treatment options are limited. We aimed to evaluate the efficacy and safety of apatinib, an angiogenesis inhibitor, in advanced TETs. METHODS: This was an open-label, single-arm, phase II trial at three centers in China. Patie...
Autores principales: | Song, Zhengbo, Lou, Guangyuan, Wang, Yina, Yang, Zhiping, Wang, Wenxian, Ji, Yongling, Chen, Shiqing, Xu, Chunwei, Hu, Xiao, Zhang, Yiping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9088066/ https://www.ncbi.nlm.nih.gov/pubmed/35534877 http://dx.doi.org/10.1186/s12916-022-02361-w |
Ejemplares similares
-
Salvage treatment with apatinib for advanced non-small-cell lung cancer
por: Song, Zhengbo, et al.
Publicado: (2017) -
Efficacy and safety of immune checkpoint inhibitors (ICIs) combined with antiangiogenic therapy for thymic epithelial tumors (TETs): a retrospective study
por: Xiang, Jing, et al.
Publicado: (2023) -
Rare frequency of gene variation and survival analysis in thymic epithelial tumors
por: Song, Zhengbo, et al.
Publicado: (2016) -
Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial
por: Song, Zhengbo, et al.
Publicado: (2022) -
A Comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients with acquired EGFR‐TKI resistance
por: Wang, Wenxian, et al.
Publicado: (2016)